Nitto Denko Avecia
Milford, MA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-29
80.3
Signal Score
✓ FDA Inspections (2)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Nitto Denko Avecia
- Signal Score
- 80.3/100 (as of 2026-04-29)
- Quality Compliance
- 100.0/100
- Headquarters
- Milford, MA
- Modalities
- Oligonucleotide, mRNA
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Nitto Denko Avecia
Major oligonucleotide CDMO. Capacity expansion underway.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA Inspections2 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-07-25)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, mRNA
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
68.0
Parent company: Nitto Denko (6988.T)
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Nitto Denko (6988.T)
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Milford, MA
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Sites: Milford, MA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Milford, MA
Modalities: Oligonucleotide, mRNA
Capacity assessment: 58.0/100
Nitto Denko Avecia FDA Inspection History
2025-07
2024-08
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-07-25 | Irvine, California | Drug Quality Assurance | No | No Action Indicated (NAI) |
| 2024-08-20 | Cincinnati, Ohio | Drug Quality Assurance | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Jul 04, 2026
Frequently Asked Questions About Nitto Denko Avecia
How many FDA inspections does Nitto Denko Avecia have on record?
CDMO Signal tracks 2 FDA inspections for Nitto Denko Avecia, sourced from the FDA inspection database. See the full inspection history above.
Has Nitto Denko Avecia received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Nitto Denko Avecia.
What is Nitto Denko Avecia's CDMO Signal Score?
Nitto Denko Avecia has a Signal Score of 80/100, based on quality, operations, financial stability, and capacity data.
Evaluating Nitto Denko Avecia for a manufacturing program?
Use the free AI matchmaker to compare Nitto Denko Avecia against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 82.5
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 80.3
mRNA, Plasmid, Oligonucleotide
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.4
mRNA, Oligonucleotide, Biologics
ST Pharm
Seoul, KR
Signal Score: 72.8
Oligonucleotide, mRNA
TriLink BioTechnologies
San Diego, CA
Signal Score: 71.0
mRNA, Oligonucleotide